OMEGA PHARMA INNOVATION & DEVELOPMENT

Active

Public limited companyfounded 2006active for 20 yearsGaston Crommenlaan 6, 9050 Gent, Belgium23 active companies are registered at this addressKBO/BCE: BE 0884.084.724

Summary

OMEGA PHARMA INNOVATION & DEVELOPMENT has been active since 2006 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €240.2m and a net result of €11.4m. Equity is shrinking by about 23% per year across the filed financial years. Its solvency ranks better than 93% of 239 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Risk analysisFollow Report Compare

OMEGA PHARMA INNOVATION & DEVELOPMENTActiveChecked score 95/100

Risk analysis Report Compare

Activity

Other research and development on natural sciences

NACE 72109Research and development on biotechnology NACE 72101

3rd largest company by equity in East Flanders, Research and development sector1 site

Size

€16.3mturnover 2025

Staff: 38.2 FTE
Equity: €240.2m
Profit: €11.4m

Financial health

95 Excellent Checked score 2025

Bankruptcy probabilitywithin 12 months: 0.1%

Structure

Parent: Perrigo Holding · 100%
Holdings: 1

Sonia HolliesManaging director
Jonas DhaenensDirector

Auditor: BDO Bedrijfsrevisoren bv2025 accounts 24 days early6 of 37 deeds summarised

Why 95raises riskLiquidity: current ratio 37.67, cash €7,220lowers riskSize: turnover €16.3m, 38.2 FTE, total assets €246.6mEquity €240.2m (97.4% of total assets)Founded in 2006Show the evidence

Checked score

Score 2025

95 / 100

Excellent

Probability in this band: under 0.55%

Financially better than 59% of its sector peers (NACE 72, small)

Every signal that counts is listed under Signals.

Financial strength · tick = 2023

Strong

Solvency 100=

equity 97.4% of total assets

Liquidity 50+5

short-term debt 2.6% · cash 0.0%

Profitability 64-20

return on assets 4.6%

Bankruptcy probability, 12 months

0.1% Very low

0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (165 companies, NACE 72, small)

Last 24 months 11-2024: 0.2% 12-2024: 0.2%● unchanged vs 11-2024 01-2025: 0.2%● unchanged vs 12-2024 02-2025: 0.2%● unchanged vs 01-2025 03-2025: 0.2%● unchanged vs 02-2025 04-2025: 0.3%▲ +0.1 percentage points vs 03-2025 05-2025: 0.3%● unchanged vs 04-2025 06-2025: 0.3%● unchanged vs 05-2025 07-2025: 0.3%● unchanged vs 06-2025 08-2025: 0.4%▲ +0.1 percentage points vs 07-2025 09-2025: 0.6%▲ +0.2 percentage points vs 08-2025 10-2025: 1.1%▲ +0.5 percentage points vs 09-2025 11-2025: 1.1%● unchanged vs 10-2025 12-2025: 1.2%▲ +0.1 percentage points vs 11-2025 01-2026: 1.6%▲ +0.4 percentage points vs 12-2025highest value 02-2026: 1.6%● unchanged vs 01-2026highest value 03-2026: 1.6%● unchanged vs 02-2026highest value 04-2026: 0.9%▼ -0.7 percentage points vs 03-2026 05-2026: 0.9%● unchanged vs 04-2026 06-2026: 0.9%● unchanged vs 05-2026 07-2026: 0.9%● unchanged vs 06-2026 08-2026: 0.1%▼ -0.8 percentage points vs 07-2026lowest value 09-2026: 0.1%● unchanged vs 08-2026lowest value 10-2026: 0.1%● unchanged vs 09-2026lowest value

Credit of up to €1,600,000 on 30-day terms is acceptable

Liquidity ample (current ratio 37.67, compared with 2.36 in 2023, above the usual 1.5; short-term debt: 2.6% and cash: 0% of total assets), and 2.6% of the assets are financed with debt and provisions.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, small): better than 85% on solvency, 39% on liquidity and 53% on profitability.

The bankruptcy probability was computed on 25-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.

lowers riskraises riskneutral

Liquidity: current ratio 37.67, cash €7,220

NBB · annual accounts

Size: turnover €16.3m, 38.2 FTE, total assets €246.6m

Companies of this size fail less often; how much that weighs depends on the rest of its profile.

NBB · annual accounts

Equity €240.2m (97.4% of total assets)

NBB · annual accounts

Founded in 2006

Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.

KBO

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 07-07-2026, 24 days ahead of the deadline.

NBB · 10 filings

Deviation from the deadline

2025

24 days early

2024

43 days early

2023

70 days early

2022

67 days early

2021

44 days early

2020

47 days early

2019

50 days early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 49 days before the deadline; the sector median (NACE 72) for financial year 2024 is 13 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 17 June (5 of the last 5 filed years within 30 days of that day).

Companies Code · seven months

Where today falls in the filing period

25-10-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

Searched since 2021.

KBO publications · our coverage

07-07-2026 Annual accounts filedfinancial year 2025 · full…
08-06-2026 Resignation: Anja van Winsberghe (director)Appointment: Jonas Dhaenens (director) ·…
31-12-2025 Highest result from 2018 to 2025net €11.4m ▲16.7%

Key points

Positive: Among the best 5% on net resultsector median €3,198 · 237 companies €11.4m View
Positive: Filed on time since financial year 2018accounts within the deadline every year 8 years View
Controlled by Perrigo Holdingultimately: Perrigo Company Plc 100% View
Board changedlatest change 22-05-2026 · 2 in office 1 joined · 1 left View

By topic

Financials

Financial year: 2025
Turnover: €16.3m
Profit: €11.4m
Solvency: 97.4%

Turnover▼ 70.4%

Net result

20182025

Go to Financials

Board & ownership

Board: 2 members
Parent: Perrigo Holding · 100%
Auditor: BDO Bedrijfsrevisoren bv

Sonia HolliesManaging director
Jonas DhaenensDirector

Go to Board & ownership

Network & group

Group: Perrigo Company Plc
Subsidiaries: 1
Mergers and asset contributions: 1

1 subsidiary

Go to Network & group

Timeline

Events: 29
Since: 2009
Next accounts: by 31-07-2027

31-12-2025Liquidity more than 15 times
22-12-2025Resignation: EY Bedrijfsrevisoren BV (statutory auditor)
18-06-2025Annual accounts filed

Go to Timeline

Company details

Sites: 1

Legal form: Public limited company
Activity: Other research and development on natural sciencesNACE 72109
Founded: 09-10-2006
Year ends: 31-12
Peppol: Reachable for e-invoices

Go to Company details

Articles of association

Provisions read: 6

See the provisions in the deeds

Go to Articles of association

Key facts about OMEGA PHARMA INNOVATION & DEVELOPMENT

What is the company number of OMEGA PHARMA INNOVATION & DEVELOPMENT?: 0884.084.724. In Belgium the VAT number is the company number with BE in front: BE 0884.084.724.
Where is OMEGA PHARMA INNOVATION & DEVELOPMENT based?: The registered office is at Gaston Crommenlaan 6, 9050 Gent.Company details
What does OMEGA PHARMA INNOVATION & DEVELOPMENT do?: According to the KBO register, the main activity is other research and development on natural sciences (NACE 72109).
What is the legal form of OMEGA PHARMA INNOVATION & DEVELOPMENT?: Public limited company (NV).
When was OMEGA PHARMA INNOVATION & DEVELOPMENT founded?: On 09-10-2006.
Is OMEGA PHARMA INNOVATION & DEVELOPMENT still active?: Yes, OMEGA PHARMA INNOVATION & DEVELOPMENT is an active enterprise in the KBO register.
How many employees does OMEGA PHARMA INNOVATION & DEVELOPMENT have?: On average 38.2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of OMEGA PHARMA INNOVATION & DEVELOPMENT?: €16.3m in financial year 2025, according to the filed annual accounts.
Is OMEGA PHARMA INNOVATION & DEVELOPMENT profitable?: In financial year 2025, OMEGA PHARMA INNOVATION & DEVELOPMENT made a profit of €11.4m.
Where can I find the annual accounts of OMEGA PHARMA INNOVATION & DEVELOPMENT?: OMEGA PHARMA INNOVATION & DEVELOPMENT filed 19 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of OMEGA PHARMA INNOVATION & DEVELOPMENT due?: By 31-07-2027, for financial year 2026.Timeline